Dietrich Wilhelm Beelen, Rudolf Trenschel, Matthias Stelljes, Christoph Groth, Tamás Masszi, Péter Reményi, Eva-Maria Wagner-Drouet, Beate Hauptrock, Peter Dreger, Thomas Luft, Wolfgang Bethge, Wichard Vogel, Fabio Ciceri, Jacopo Peccatori, Friedrich Stölzel, Johannes Schetelig, Christian Junghanß, Christina Grosse-Thie, Mauricette Michallet, Hélène Labussiere-Wallet, Kerstin Schaefer-Eckart, Sabine Dressler, Goetz Ulrich Grigoleit, Stephan Mielke, Christof Scheid, Udo Holtick, Francesca Patriarca, Marta Medeot, Alessandro Rambaldi, Maria Caterina Micò, Dietger Niederwieser, Georg-Nikolaus Franke, Inken Hilgendorf, Nils Rudolf Winkelmann, Domenico Russo, Gérard Socié, Régis Peffault de Latour, Ernst Holler, Daniel Wolff, Bertram Glass, Jochen Casper, Gerald Wulf, Helge Menzel, Nadezda Basara, Maria Bieniaszewska, Gernot Stuhler, Mareike Verbeek, Sandra Grass, Anna Paola Iori, Juergen Finke, Fabio Benedetti, Uwe Pichlmeier, Claudia Hemmelmann, Michael Tribanek, Anja Klein, Heidrun Anke Mylius, Joachim Baumgart, Monika Dzierzak-Mietla, Miroslaw Markiewicz
BACKGROUND: Further improvement of preparative regimens before allogeneic haemopoietic stem cell transplantation (HSCT) is an unmet medical need for the growing number of older or comorbid patients with acute myeloid leukaemia or myelodysplastic syndrome. We aimed to evaluate the efficacy and safety of conditioning with treosulfan plus fludarabine compared with reduced-intensity busulfan plus fludarabine in this population. METHODS: We did an open-label, randomised, non-inferiority, phase 3 trial in 31 transplantation centres in France, Germany, Hungary, Italy, and Poland...
January 2020: Lancet Haematology